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Despite late complications related to radiation therapy, RT 
remains a standard component of treatment among pediatric 
patients.                                                                               
The current aim of many pediatric clinical trials is to reduce 
dose and volume of irradiation to decrease side effects 
without affecting the rate of local control using multi-
modality treatment. 
Recent advances in radiotherapy technology contribute also 
to improve therapeutic ratio thanks to better conformal dose 
distribution and avoidance of surrounding critical structures. 
Integration of multimodal imaging in target delineation, use 
of CT for treatment planning (3D conformal radiation 
therapy) and immobilization devices have significantly 
decreased clinical and planning target volume margins. 
Intensity modulated radiation therapy could be particularly 
useful in cases of complex and large volume closed to critical 
structures.  While high dose to neighboring structures can be 
selectively decreased by the means of IMRT, low dose is 
raised in the rest of the body with theoretical increased risk 
of secondary malignancies or unexpected toxicities related to 
irradiation of very sensitive organs at risk located at distance 
of target volume. Number of prospective studies comparing 
IMRT to 3D CRT is low. However available data suggest that 
IMRT provided local control equivalent to 3D CRT with 
favorable short term toxicity profile and reduction of some 
sequelae.  No excess of second tumor is described but follow-
up is still limited.   
Concerning strategies for management of internal target 
movement due to respiratory motion, the more widespread 
modality in pediatric radiotherapy is 4-dimensional CT for 
radiation. Other techniques such as active breathing control 
or respiratory gating is not widely widespread because their 
use is conditioned by collaboration ability and patient age. 
Up to now stereotactic radiation therapy has been mainly 
used in childhood for intracranial benign disease by 
neurosurgeon. However development of non-invasive 
repositioning system and LINAC dedicated to stereotactic 
irradiation gives the opportunity of hypofractionated 
treatment of metastasis or recurrence in previously 
irradiated field with minimal impact of quality of live in 
palliative setting.   
With high precision techniques, reproducibility in daily set-up 
becomes more critical to prevent geographic misses and 
image-guided RT (IGRT) has become a common practice of 
care for children as for the adults. One of the most applied 
IGRT technique is cone-beam computed tomography (CBCT). 
A limitation in use of CBCT among pediatric population is the 
extra dose deposit to critical structures witch is higher in 
children than in adults. Because of potential of yielding a 
secondary cancer at long term, it is essential to adapt 
scanning protocol when CBCT is applied to pediatric cancer 
patients routinely. 
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Neuroblastoma, predominantly a cancer of young children, is 
derived from the sympathetic nervous system. Patients are 
risk-stratified by age, stage and molecular pathology to guide 
treatment and predict outcome. High-risk neuroblastoma, 
usually defined as metastatic disease over the age of one 
year, or the presence of MYCN amplification, is the most 
common risk group, and carries a high mortality. New and 
better treatments are necessary.  
Neuroblastoma cells usually express the Noradrenaline 
Transporter (NAT) molecule which takes up meta-
Iodobenzylguanidine (mIBG), a noradenaline analogue. 
Labelled with iodine-123 for imaging or iodine-131 for 
therapy, mIBG has been used clinically in neuroblastoma and 
other NAT expressing tumours for about 30 years. Semi-
quantitative scoring of 123I-mIBG scintigraphy has become the 
gold standard imaging technique for staging, response 
assessment and follow-up of patients with neuroblastoma. 
Molecular radiotherapy with 131I-mIBG is an attractive 
treatment option for children with high-risk metastatic 
neuroblastoma because (1) the disease is disseminated, 
making local therapies alone inadequate, (2)  123I-mIBG 
scintigraphy is a predictive imaging biomarker for avid 
accumulation of 131I-mIBG in the primary tumour and 
metastatic sites, and (3) neuroblastoma is often relatively 
radiosensitive meaning impressive responses to treatment 
can be seen. 
Initially used in relapsed patients with only palliative intent, 
the use of 131I-mIBG therapy has in recent years has been 
brought forward in the course of the illness as either a first- 
or second-line strategy with the aim of increasing the 
prospects for cure. Further research efforts, especially 
randomised trials, are however needed to demonstrate its 
true value. 
The principal and therefore dose-limiting toxicity of 131I-mIBG 
therapy is haematological. The whole body absorbed 
radiation dose correlates with the haematological toxicity, 
and so whole body dosimetry can be used, in conjunction 
with peripheral blood stem cell support, to allow the use 
of higher administered activities than were previously 
considered safe. There is laboratory evidence to support the 
hypothesis that improvements in outcome may possibly be 
achieved by the simultaneous use of radiosensitising drugs 
such as topoisomerase I inhibitors. Initial clinical experience 
has been published, and clinical trials using irinotecan and 
topotecan in conjunction with 131I-mIBG are in progress or 
planned to evaluate this approach further. 
There are practical challenges when young children need to 
receive high administered activities of 131I-mIBG. The use of 
comforters and carers, usually the child's parents, is an 
essential addition to medical and nursing care. All individuals 
involved need to appreciate the risks, and be trained in 
sensible radiation protection precautions. 
Other forms of molecular radiotherapy for neuroblastoma are 
being investigated, particularly peptide receptor radionuclide 
therapy targeting the somatostatin receptor, using 
radiolabelled somatostatin analogues. Examples are 90Y-
DOTATOC and 177Lu-DOTATATE. These are not necessarily 
alternatives to 131I-mIBG therapy. Both immunohistochemical 
studies of NAT and somatostatin receptor expression in 
neuroblastoma tissue, and imaging comparisons of 123I-mIBG 
scintigraphy and 68Ga-DOTATATE PET/CT demonstrate a 
heterogeneity of appearances suggesting that they may be 
complementary. 
This presentation reviews the published evidence in relation 
to 131I-mIBG therapy for neuroblastoma, and describes the 
plans to further evaluate its place through clinical trials in 
the context of other systemic treatments for this hard-to-
cure disease. 
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Purpose/Objective: Ependymoma is the third most common 
primary brain tumor in children. Radiotherapy is 
systematically delivered after surgery. However, more than a 
third of children experience relapse locally or around the 
resection cavity wall.  
One important factor influencing clinical outcome after 
radiotherapy is the reduced oxygen levels (hypoxia). Major 
noninvasive technique suggested as capable of monitoring 
tumour hypoxia involves MR, and includes both perfusion MRI 
(by dynamic contrast-enhanced MRI, DCE) and diffusion-
weighted imaging (DWI).  
The aim of this study was to investigate if DCE or DWI MRI can 
predict radiotherapy outcome in pediatric ependymoma by 
identification of significant hypoxic subvolumes of tumors 
related to treatment outcomes and that resistance resulting 
from this hypoxia can be overcome by increasing radiation 
dose. 
Materials and Methods: 197 patients were included in this 
national retrospective study, performed in 11 french 
reference centers for pediatric radiation oncology. All 
patients underwent surgical resection and postoperative 
radiochimiotherapy. Imaging data from 93 patients could be 
retrieved. Among them eleven patients had DCE MRI and 
fifteen had DWI MRI at pre radiotherapy exam. All image 
analyses were completed using an in-house software package: 
Sisyphe. For each patient, the resection cavity was 
delineated on the post contrast T1WI. The resulting Region of 
interest (ROI) was mapped to the coregistered CBV and ADC 
map. An histogram analysis was done to determine for both 
CBV and ADC the best fitting of the data hitogramm with 2 or 
3 Gaussian functions. According to the fitting results, the 
cavity ROI was then partitioned into 2 or 3 spatial subvolumes 
using an automatic clustering method (Isodata algorithm). 
Each subvolume with the lower CBV or lower ADC was 
normalized to the ROI volume and evaluated for its 
association with outcome. 
Results: The percentage of the subvolumes with low ADC, 
was not signi?cantly different between the patients with 
Local Failure (LF) and local control (LC) (p = 0.9). The 
percentage of the subvolumes with low CBV, were 
signi?cantly greater, in the patients with LF than with LC ( p 
= 0.025). The ROC analysis indicates that for a subvolume of 
69 % of the volume ROI with low CBV had greater speci?city 
for prediction of local failure (specificity =80%, 
sensibility=100%). 
Conclusions: In our study perfusion MRI was a predictive 
factor of radiotherapy outcome in pediatric ependymoma. 
This is a promising finding as radio resistance resulting from 
hypoperfusion and consequent hypoxia could be overcome by 
increasing radiation dose to the poorly perfused defined 
subvolumes. Confirmation of our imaging data is in progress 
with completion of our database that will allow to present 
our final results to the meeting.  
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Purpose/Objective: to investigate the influence on Event 
free survival ( EFS) and overall survival ( OS ) of main 
characteristics of patients, disease and treatments for 
pediatric patients with localised ependymoma in a national 
cohort 
Materials and Methods: A total of 177 patients with newly 
diagnosed intracranial ependymoma were treated with 
adjuvant Radiation therapy (RT) in the 11 French major 
radiation oncology centers between January 2000 and 
December 2013.  
Clinical data were retrospectively gathered on a web-based 
national database between March and October 2014. 
Results: Location was posterior fossa in 77%, supratentorial 
in 23 %. Anaplastic features were present in 56% of patients. 
The extent of resection was characterized as gross-total in 
86% patients and subtotal in 14%. The median dose to the 
primary site was 59.4 Gy, 37% of patients received a dose ≤54 
Gy. Fifty-one patients received pre-RT chemotherapy. RT was 
3D conformal in 107 patients, IMRT in 60 (of which 18 
tomotherapy) and protontherapy in 10. 
With a median follow up time of 43.1 months from the start 
of RT (95%CI (33,5-52.6)), the 3-years local relapse-free 
survival (LRFS) was 67,8%. Recurrences after RT occurred in 
73 patients (41%) and were mainly local (strictly local in 62% 
of recurrences, local and distant in 7% and strictly distant in 
25%). 
The RT dose significantly influenced overall survival (OS) and 
event-free survival (EFS) after RT. The estimated 3-year OS 
and EFS rates were respectively 90 % and 67% for patients 
who received a dose > 54Gy compared with 79% and 52% for 
patients who received a dose ≤54 Gy (respectively p= 0.008 
and p=0.02). OS and EFS at 3 years were significantly 
improved for patients older than 3 years of age at the 
initiation of RT (92 and 68%) compared to children younger 
than 3 years (71 and 43%) (p=0.0007 and p=0.0001). EFS at 3 
years was greater in grade 1-2 (74%) than in grade 3-4 (53%) 
(p=0.004), OS was also greater in grade 1-2 (97%) than grade 
3-4 (81%) but this was not statistically significant.  
There was no significant difference in OS or EFS regarding the 
quality of surgery, the use of chemotherapy or the technique 
of radiotherapy.  
Conclusions: This large multicentric French cohort confirms 
that a dose > 54 Gy improved survival in localised cerebral 
ependymoma. Age younger than 3 years at initiation of RT 
and grade 3-4 were significant prognostic factors of worse 
outcome. 
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